Eidos Therapeutics, A Bridgebio Company

This study looks at the long-term safety of a drug called acoramidis in people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). All 389 participants had already completed a 30-month earlier trial of the same drug. They will now receive acoramidis for …